Transscleral neodymium:YAG laser cyclophotocoagulation for end-stage glaucoma, refractory glaucoma, and painful blind eyes.
We used transscleral Neodymium:YAG laser cyclophotocoagulation (TSYLCC) to treat 47 patients (47 eyes) with end-stage, refractory, or absolute glaucoma. The mean pretreatment intraocular pressure (IOP), 40.5 +/- 10.8 mm Hg, decreased a mean of 13 +/- 8 months following treatment to 15.6 +/- 10.6 mm Hg, a statistically significant change (P < .05). Our overall rate of success (final IOP < or = 25 mm Hg, with or without medications) was 79% (37 eyes). Early complications included pain (11 eyes) and inflammation (13 eyes); late complications included hypotony (7 eyes), high IOP (5 eyes), and decreased visual acuity (4 eyes). TSYLCC seems to be a safe, effective, and convenient outpatient procedure.
al-Ghamdi
S
S
King Fahad Hospital at Al-Baha, Kingdom of Saudi Arabia.
al-Obeidan
S
S
Tomey
K F
KF
al-Jadaan
I
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001766:Blindness / Q000503:physiopathology / Q000601:surgery*; D002924:Ciliary Body / Q000601:surgery*; D004837:Epinephrine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure; D017075:Laser Coagulation; D008875:Middle Aged; D010146:Pain / Q000601:surgery; D011183:Postoperative Complications; D012590:Sclera; D013999:Timolol / Q000627:therapeutic use; D014792:Visual Acuity
D013999:Timolol; C015173:dipivefrin; D004837:Epinephrine